Search results for "vaccination."

showing 10 items of 654 documents

The Italian Version of the Adult Vaccine Hesitancy Scale (aVHS) for the Working-Age Population: Cross-Cultural Adaptation, Reliability, and Validity

2022

The adult Vaccine Hesitancy Scale (aVHS) is valid and reliable for evaluating attitudes toward vaccine preventable diseases (VPDs). The aim of the present study was to evaluate the cross-cultural adaptation, reliability, and validity of the Italian version of the aVHS. After cross-cultural adaptation of the aVHS, internal consistency (IC), intra-class correlation (ICC), and content validity (S-CVI) were evaluated through a survey on 160 workers. Results of the ICC were analyzed on questionnaires administered twice at a distance of two months and revealed a satisfactory reproducibility (0.87). The IC of the aVHS was assessed by the Cronbach alpha coefficient test, with a result of 0.94, demo…

Vaccine preventable diseasePharmacologySARS-CoV-2VaccinationImmunologyCOVID-19vaccination; workplace; SARS-CoV-2; vaccine hesitancy; Italy; worker; COVID-19; vaccine preventable diseaseSARS‐CoV‐2Infectious DiseasesItalyCOVID‐19Drug DiscoveryWorkerPharmacology (medical)WorkplaceVaccine hesitancyVaccines
researchProduct

Initiation of adaptive immune responses by transcutaneous immunization.

2007

The development of new, effective, easy-to-use and lower-cost vaccination approaches for the combat against malignant and infectious diseases is a pre-eminent need: cancer is a leading cause of morbidity in the Western World; there are numerous pathogenic diseases for which we still have no protective or therapeutic cure; and the financial limitations of developing countries to fight these diseases. In this mini-review we focus on transcutaneous immunization (TCI), a relatively new route for antigen delivery. TCI protocols appear to be particularly promising by gaining access to skin resident APC, which are highly efficient for the initiation of humoral and/or cellular immune responses. Con…

Vaccinesbiologymedicine.medical_treatmentImmunologyReverse vaccinologyReceptors Lymphocyte HomingTLR7Major histocompatibility complexAdministration CutaneousEpitopeVaccinationImmune systemImmunity ActiveAntigenImmunologymedicinebiology.proteinImmunology and AllergyAnimalsHumansImmunizationAdjuvantImmunology letters
researchProduct

Vaccines Through Centuries: Major Cornerstones of Global Health

2015

Multiple cornerstones have shaped the history of vaccines, which may contain live-attenuated viruses, inactivated organisms/viruses, inactivated toxins, or merely segments of the pathogen that could elicit an immune response. The story began with Hippocrates 400 B.C. with his description of mumps and diphtheria. No further discoveries were recorded until 1100 A.D. when the smallpox vaccine was described. During the eighteenth century, vaccines for cholera and yellow fever were reported and Edward Jenner, the father of vaccination and immunology, published his work on smallpox. The nineteenth century was a major landmark, with the "Germ Theory of disease" of Louis Pasteur, the discovery of t…

Vaccinesbusiness.industryViral VaccineDiphtherialcsh:Public aspects of medicineVaccine controversiesVaccinationhistory of vaccinesPublic Health Environmental and Occupational Healthglobal healthlcsh:RA1-1270Reviewmedicine.diseaseVirologyhumanitiesVaccinationImmunizationmedicinePertussis vaccineSmallpoxImmunizationPublic HealthbusinessSmallpox vaccinemedicine.drugFrontiers in Public Health
researchProduct

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra: immunogenicity and safety profile

2009

Abstract Priorix-Tetra ™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR ( Priorix ™) and varicella ( Varilrix ™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into rou…

Varicella vaccineImmunization Secondarymedicine.vaccineAntibodies ViralRubellaMeaslesChickenpox VaccinemedicineHumansVaccines CombinedChildClinical Trials as TopicReactogenicityMMRV vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantvirus diseasesmedicine.diseaseVirologyVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular MedicinebusinessMeasles-Mumps-Rubella Vaccine
researchProduct

MMR and MMRV vaccines.

2018

Measles, mumps, rubella and varicella are viral infections which can implicate seriously long-term sequelae of infected individuals or even the unborn child. Vaccines against the individual diseases have long been available. Global measles vaccination is estimated to have prevented more than 20million deaths during 2000-2015. During the same time period, measles incidence decreased from 146 to 36 cases per million populations. Today vaccinations against measles, mumps, rubella and varicella are now carried out mainly with combination vaccines. These are today known as immunogenic and safe. MMRV had similar immunogenicity and overall safety profiles to MMR administered with or without varice…

Varicella vaccineRubellaMeasles03 medical and health sciences0302 clinical medicineChickenpox030225 pediatricsmedicineHumans030212 general & internal medicineAdverse effectMumpsRubellaVaccinesGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityIncidence (epidemiology)VaccinationPublic Health Environmental and Occupational Healthvirus diseasesmedicine.diseaseVaccinationInfectious DiseasesImmunizationImmunologyMolecular MedicinebusinessMeaslesVaccine
researchProduct

Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us – and what they don't

2021

In the present issue of the Journal [1], Smadja et al. present an analysis of global pharmacovigilance reports of thrombotic events following severe acute respiratory distress syndrome coronavirus (SARS-CoV)-2 vaccination. More specifically, the authors analysed the data entered into the World Health Organization (WHO) Global Database for Individual Case Safety Reports (VigiBase) between December 13, 2020 and March 16, 2021, covering, at that time, a population of almost 362 million vaccinated individuals across the world. The study focuses on three of the coronavirus disease (COVID)-19 vaccines available to date, namely the Pfizer-BioNtech (BNT162b2), Moderna (mRNA-1273), and OxfordAstraZe…

Venous ThrombosisPulmonary and Respiratory Medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)SARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationCOVID-19ThrombosisVaccination03 medical and health sciencesEditorial0302 clinical medicine030228 respiratory systemPharmacovigilancemedicineHumans030212 general & internal medicineIntensive care medicinebusinessThrombotic complicationEuropean Respiratory Journal
researchProduct

Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure

1990

Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure. Only 50 to 60% of dialysis patients develop anti-HBs antibodies following hepatitis b vaccination. The nonre-sponder state correlates with impaired monocyte function, decreased interleukin-2 (IL-2) production of T cells, and an upregulation of the IL-2 receptor system. In the present study we examined anti-HBs production after hepatitis B vaccination and the in vitro expression of IL-2 receptors in nondialyzed patients with various degrees of chronic renal failure. Forty-four patients with impaired renal function were immunized with 20 µg recombinant hepatitis B vaccine and boostered after one and six mo…

Viral Hepatitis VaccinesT-LymphocytesReceptor expressionmedicine.disease_causechemistry.chemical_compoundmedicineHumansHepatitis B VaccinesProspective StudiesHepatitis B AntibodiesSeroconversionHepatitis B virusVaccines SyntheticCreatininebiologybusiness.industryVaccinationAntibody titerReceptors Interleukin-2Middle AgedHepatitis Bbiology.organism_classificationVaccinationchemistryHepadnaviridaeNephrologyAntibody FormationImmunologybiology.proteinKidney Failure ChronicAntibodybusinessKidney International
researchProduct

July 2003: 62-year-old female with progressive muscular weakness

2004

The July 2003 Case of the Month (COM). A 62-year-old female patient experienced progressive muscular weakness over the last ten years, involving shoulder and pelvic girdle muscles, paraspinal and facial muscles. A biopsy was taken from the left deltoid muscle where hepatitis vaccination had taken place 4 weeks previously. The specimen revealed macrophagic myofasciitis due to the injection of aluminium-bound vaccines. The finding can be reproduced experimentally by injecting vaccines in rats. The pathomechanism is supposed to involve immune stimulation due to long term persistence of the adjuvant. Macrophagic myofasciitis has been suggested to occasionally cause myopathy but is supposed to b…

Viral Hepatitis Vaccinesmedicine.medical_specialtyAluminum HydroxideMass SpectrometryCases of the Month: July to September 2003Pathology and Forensic MedicineDiagnosis DifferentialBiopsymedicineHumansMuscle SkeletalMyopathyInclusion BodiesHepatitisMuscle WeaknessPelvic girdlemedicine.diagnostic_testbusiness.industryMacrophagesGeneral NeuroscienceMacrophagic myofasciitisMiddle Agedmedicine.diseaseMuscular Dystrophy FacioscapulohumeralSurgeryVaccinationMicroscopy ElectronFacial musclesmedicine.anatomical_structureFemaleNeurology (clinical)medicine.symptombusinessProgressive muscular weaknessBrain Pathology
researchProduct

Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice

2014

Coxsackievirus B3 (CVB3) is an important cause of acute and chronic viral myocarditis, and dilated cardiomyopathy (DCM). Although vaccination against CVB3 could significantly reduce the incidence of serious or fatal viral myocarditis and various other diseases associated with CVB3 infection, there is currently no vaccine or therapeutic reagent in clinical use. In this study, we contributed towards the development of a CVB3 vaccine by establishing an efficient and scalable ion exchange chromatography-based purification method for CVB3 virus and baculovirus-insect cell-expressed CVB3 virus-like particles (VLPs). This purification system is especially relevant for vaccine development and produ…

Viral MyocarditisvirusesIon chromatographyGenetic VectorsCoxsackievirus InfectionsBiologyAntibodies ViralVirus03 medical and health sciencesMice0302 clinical medicineImmune systemVirus-like particleAntibody SpecificityVirologyGene OrderAnimalscardiovascular diseases030212 general & internal medicineVaccines Virus-Like Particle030304 developmental biologyPharmacology0303 health sciencesImmunity Cellularta1182virus diseasesmusculoskeletal systemChromatography Ion ExchangeVirology3. Good healthEnterovirus B HumanVaccinationDisease Models AnimalImmunizationCoxsackievirus b3cardiovascular systemFemaleImmunizationBaculoviridaeAntiviral Research
researchProduct

Booster vaccination after neonatal priming with acellular pertussis vaccine.

2010

After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/ Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

Whooping CoughFilamentous haemagglutinin adhesinImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesVirusPolio vaccineVaccines AcellularmedicineHumansWhooping coughHepatitis B virusPertussis VaccineDose-Response Relationship Drugbusiness.industryDiphtheriaVaccinationInfant Newbornvirus diseasesInfantmedicine.diseasePrognosisVirologyVaccinationPediatrics Perinatology and Child HealthImmunologybusinessFollow-Up StudiesThe Journal of pediatrics
researchProduct